The basal ganglia network serves to integrate information about context, actions, and outcomes to shape the behavior of an animal based on its past experience. Clinically, the basal ganglia receive the most attention for their role in movement disorders. Recent advances in technology have opened new avenues of research into the structure and function of basal ganglia circuits. One emerging theme is the importance of GABAergic interneurons in coordinating and regulating network function. Here, we discuss evidence that changes in striatal GABAergic microcircuits contribute to basal ganglia dysfunction in several movement disorders. Because interneurons are genetically and neurochemically unique from striatal projection neurons, they may provide promising therapeutic targets for the treatment of a variety of striatal-based disorders.
Introduction
The 1980s were a golden era for basal ganglia research, culminating in circuit models that continue to guide hypothesis-based studies of basal ganglia function in clinical and experimental contexts [1] [2] [3] [4] . Within the basal ganglia, the striatum is the most prominent nucleus, serving as a major site of input and integration for cortical, thalamic, and midbrain afferents. The striatum is functionally divided along a dorsolateral/ventromedial axis, where the dorsolateral portion subserves sensorimotor functions and the ventromedial portion is more involved in cognitive and limbic functions [5] . Because the focus of this review is neural circuits involved in movement disorders, much of our discussion is concentrated on neural circuits in the dorsolateral striatum.
The projection neurons of the striatum, termed spiny projection neurons (SPNs), integrate glutamatergic inputs from the cortex and thalamus and send GABAergic projections to neurons in downstream basal ganglia nuclei. Based on anatomical projection patterns and biochemical differences, SPNs are divided into two classes. D1-type dopamine receptor-expressing neurons project directly to basal ganglia output nuclei, and are termed 'direct-pathway' SPNs (dSPNs), whereas D2-type dopamine receptor-expressing neurons, known as 'indirect-pathway' SPNs (iSPNs), project indirectly to basal ganglia output nuclei via the globus pallidus external segment (GPe) and the subthalamic nucleus (STN). These pathways are well segregated in the dorsolateral striatum, and fewer than 5% of SPNs express both classes of dopamine receptors [6] . Activity of dSPNs leads to the disinhibition of motor circuits to facilitate movement. Overactivity of the direct pathway has been proposed to cause hyperkinetic movement disorders such as Huntington's disease (HD), dystonia, and Tourette's syndrome. By contrast, iSPN activity inhibits motor circuits to suppress movement. Overactivity of the indirect pathway is thought to underlie hypokinetic motor symptoms in disorders such as Parkinson's disease (PD).
Approximately 80-90% of striatal SPNs in the dorsolateral striatum fall into the direct/indirect pathway classification system. The remaining 10-20% are found in neurochemically distinct patches throughout the striatum, termed striosomes or patches [4] . SPNs in striosomes typically express D1 receptors and project directly to a subset of dopaminergic neurons in the substantia nigra compacta (SNc). Their direct projections to a subset of dopamine neurons suggest that striosomal SPNs are particularly important for regulating dopamine signaling, but their immediate effects on movement are not clear.
These classic models of basal ganglia function illustrate the importance of understanding how and when specific classes of SPNs are activated. Historically, the cellular and synaptic mechanisms controlling dSPN versus iSPN activation were difficult to elucidate because SPN subtypes could only be differentiated using manually intensive anatomical methods or antidromic stimulation in vivo. This has rapidly changed thanks to the development of transgenic mouse lines that fluorescently label dSPNs, iSPNs, and local interneurons within the striatum [7] [8] [9] [10] [11] .
Interneurons tune and regulate the dynamic properties of neural circuits in many brain regions. Interneurons comprise only 5% of all striatal neurons, but they are crucial regulators of striatal output. Compared to the broad diversity of interneuron subtypes in the hippocampus [12] and cortex [13] , interneurons in the striatum are considerably less heterogeneous (Figure 1) . Electrophysiologically, most striatal GABAergic interneurons fall into two categories: (i) fast-spiking interneurons (FSIs) and (ii) persistent and low-threshold spike (PLTSs) interneurons [14] . Neurochemically, FSIs may be distinguished by their expression of the calcium-binding protein parvalbumin (PV), whereas PLTS interneurons express neuropeptides such as somatostatin (SOM), neuropeptide Y (NPY), and the enzyme nitric oxide synthase (NOS). Neurons broadly classified physiologically because PLTSs might also include several subtypes of GABAergic interneurons,
